<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below wrt a survey by CCSN.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Participate if you wish.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Jackie Manthorne [mailto:jmanthorne@survivornet.ca] <br><b>Sent:</b> June 1, 2015 10:26 AM<br><b>To:</b> Jackie Manthorne<br><b>Subject:</b> Take part in and help us spread the news about our survey on Xgeva!<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm'><span style='font-family:"Calibri","sans-serif";color:#333333;background:white'>The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours. </span><o:p></o:p></p><div style='margin-bottom:10.0pt'><p class=MsoNormal><span style='font-family:"Calibri","sans-serif";color:#606060'>The information gathered from this survey will be used in order to prepare a patient evidence submission to the CADTH Common Drug Review. Please note that your personal information is never shared or disclosed, but is used only by CCSN for input for statistical purposes.<br></span><span style='color:#333333'><br></span><span style='font-family:"Calibri","sans-serif";color:#333333;background:white'>This survey will be open until noon on June 11, 2015 to enable us to prepare our patient evidence submission on June 16, 2015.</span><o:p></o:p></p></div><div style='margin-bottom:10.0pt'><p class=MsoNormal><span style='font-family:"Calibri","sans-serif";color:#333333;background:white'>Please pass this information to other members of your group.</span><o:p></o:p></p></div><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm'><span style='font-family:"Calibri","sans-serif";color:#333333;background:white'>Access the survey at <a href="https://www.surveymonkey.com/s/2CK7HD9">https://www.surveymonkey.com/s/2CK7HD9</a></span><o:p></o:p></p><div><p class=MsoNormal>Thanks,<o:p></o:p></p></div><div><p class=MsoNormal>Jackie<br clear=all><br>-- <o:p></o:p></p></div><div><div><div><div><div><p class=MsoNormal>Jackie Manthorne<o:p></o:p></p></div><div><p class=MsoNormal>President and CEO<o:p></o:p></p></div><div><p class=MsoNormal>Présidente et chef de la direction<o:p></o:p></p></div><div><p class=MsoNormal>Canadian Cancer Survivor Network<o:p></o:p></p></div><div><p class=MsoNormal>Réseau canadien des survivants du cancer<o:p></o:p></p></div><div><p class=MsoNormal>1750 croissant Courtwood Crescent, Suite 210<o:p></o:p></p></div><div><p class=MsoNormal>Ottawa, ON K2C 2B5<o:p></o:p></p></div><div><p class=MsoNormal>Telephone / Téléphone : 613-898-1871<o:p></o:p></p></div><div><p class=MsoNormal>E-mail / Courriel : <a href="mailto:jmanthorne@survivornet.ca" target="_blank">jmanthorne@survivornet.ca</a><o:p></o:p></p></div><div><p class=MsoNormal>Web site / site web: <a href="http://www.survivornet.ca" target="_blank">www.survivornet.ca</a><o:p></o:p></p></div><div><p class=MsoNormal>Blog: <a href="http://jackiemanthornescancerblog.blogspot.com/" target="_blank">http://jackiemanthornescancerblog.blogspot.com/</a><o:p></o:p></p></div><div><p class=MsoNormal>Twitter: @<a href="http://survivornet.ca" target="_blank">survivornet.ca</a><o:p></o:p></p></div></div></div></div></div></div></div></body></html>